

Supplemental Information

Supplemental table 1: A mitogen screen using GSCs and NPCs

	131		827		NPC1		NPC2	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
untreated control	5.389	0.180	4.744	0.068	0.812	0.204	0.750	0.204
EGF	81.417	2.242	65.917	1.083	9.917	0.110	6.833	1.167
bFGF	23.890	1.800	28.667	2.075	4.375	0.552	6.292	0.150
EGF+bFGF	111.540	5.342	74.322	4.342	12.460	2.445	8.984	1.452
HGF	27.958	1.522	12.389	0.180	3.240	0.667	2.873	0.331
beta-NGF	8.625	0.580	9.556	0.515	2.528	0.778	3.222	0.068
NT-3	5.500	0.637	3.472	0.646	0.760	0.177	0.783	0.114
BDNF	6.708	1.017	4.583	0.454	1.958	0.184	2.528	0.148
Semaphorin 3A	27.250	3.146	14.958	2.765	0.775	0.125	0.317	0.218
Semaphorin 3B	3.486	1.195	5.875	1.816	0.867	0.326	1.083	0.505
Semaphorin 3C	9.292	5.745	6.463	2.253	1.153	0.417	0.992	0.126
Semaphorin 3D	5.917	1.134	2.992	1.125	0.750	0.250	0.708	0.260
Semaphorin 3E	3.494	1.706	2.875	1.192	0.708	0.191	0.861	0.427
Semaphorin 5A	8.861	3.071	7.250	3.279	0.725	0.214	0.917	0.391
Semaphorin 6A	7.069	1.209	5.069	1.916	0.883	0.347	1.069	0.295
Semaphorin 6D	2.403	1.144	3.403	0.690	0.583	0.144	0.708	0.191
Slit3	5.917	0.813	4.617	0.586	0.750	0.250	0.792	0.315
Slit1	5.733	1.783	4.408	0.396	0.875	0.125	0.833	0.382
RGM-B	3.319	0.856	4.580	0.640	0.875	0.139	0.817	0.388
RGM-A	3.528	0.937	3.403	0.945	0.708	0.191	0.683	0.161
Ephrin-A1	3.611	2.014	3.992	0.647	0.775	0.115	0.583	0.629
Ephrin-A5	5.319	2.341	4.792	0.688	0.808	0.170	0.417	0.382
Ephrin-B2	8.653	3.623	5.125	4.823	0.692	0.201	0.708	0.191
Ephrin-B1	7.833	3.001	8.667	3.711	0.708	0.191	0.667	0.289
Neuroigin 1	4.986	0.307	5.075	0.385	0.833	0.315	1.083	0.520
Neuroigin 2	4.528	1.100	6.875	1.231	0.733	0.225	1.542	0.711
Neuroigin 3	11.861	1.737	7.542	2.688	1.336	0.604	0.950	0.189
Nogo-A	7.319	2.260	6.833	3.138	0.783	0.125	0.686	0.681
Omgp	6.490	1.593	5.235	0.936	0.828	0.423	0.932	0.782

We chose 24 recombinant proteins that are critical regulators of synaptic adhesion, axon guidance, and neurotropic functions. Both GBM cells and NPCs were plated at varying seeding densities (5 to 200 cells per well) in serum-free media and then their growth was evaluated two weeks later by counting the number of resultant spheres.

Supplemental figure legends

Figure S1. *Sema3A* induces GBM cell proliferation via *NRP1*.

(A) LDA analysis to determine clonogenic growth of GBM cells (131, 387 and 559) treated with or without r*Sema3A*. Varying number of cells (1 to 100) was seeded into the each well (30 per each condition) and allowed to grow. Wells without sphere formation were counted. * $p < 0.01$ by pairwise t test.

(B) LDA analysis to determine clonogenic growth of GSCs (131, 387, 83) with *NRP1* shRNA or with NT shRNA. * $p < 0.01$ by pairwise t test.

Figure S2. The *Sema3A-NRP1-TGF β RI* signaling axis in GBM

(A and B) Co-immunoprecipitation (Co-IP) analysis of *NRP1* and *TGF β RI* in patient derived GBM tumors (047, 050) and the derivative cells (131, 559, 83). IgG represents a control antibody used for IPs.

(C) Immunoblots of pSMAD2 and total SMAD2 expression in patient derived GBM cells (559 and 047) and NPCs treated with or without r*Sema3A*.

(D) Co-IP analyses of *NRP1* (WT), *NRP1* mutant (MT), and *TGF β RI* proteins in 387 GBM cells treated with r*Sema3A*. IgG represents a control antibody used for IPs.

(E) Immunoblots of pSMAD2 and total SMAD2 expression in V5-tagged wild type *NRP1* (WT) and *NRP1* mutant (MT) treated with or without r*Sema3A*.

(F) Short-term proliferation analysis of 387 GBM cells overexpressing the control vector, wild type *NRP1*, or *NRP1* mutant vector. These cells were treated with or without r*Sema3A*. $n = 3$. Data represent mean \pm SD. * $p < 0.01$ by one-way ANOVA with Tukey's multiple comparison test in F. NS represents non-significant.

Figure S3. Characterization of TGF β RI-T204D protein

(A) Immunoblots of TGF β RI, pSMAD2 and SMAD2 in GBM cells expressing a constitutively active TGF β type I receptor (*TGF β RI-T204D*).

(B) Short-term proliferation analysis of 131 and 559 GBM cells expressing TGF β RI-T204D protein. n = 3. Data represent mean \pm SD. *p < 0.01 by one-way ANOVA. NS represents non-significant.

(C) LDA analysis of 131 and 559 GBM cells expressing TGF β RI-T204D protein. *p < 0.01 by pairwise t test.

Figure S4. Correlations between the expression levels of *NRP1* and *Sema3A* or *TGFR β 1* in LGG/GBM specimens.

In silico analyses showing positive correlations between *NRP1* and *Sema3A* or *TGFR β 1* (n=667). r values were calculated by Pearson's correlation test. All analyses were performed using GlioVis (<http://gliovis.bioinfo.cnio.es/>) (1).

Figure S5. Correlation between *NRP1* mRNA levels and TGF β activity in gliomas.

(A) Heat map plot of glioma subtypes and TGF β activity based on the *NRP1* mRNA levels.

(B) Correlation between *NRP1* mRNA and TGF β activity in gliomas. n = 157. r values were calculated by Pearson's correlation test. *p < 0.00001

Reference

1. Bowman RL, Wang Q, Carro A, Verhaak RG, and Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. *Neuro Oncol.* 2017;19(1):139-41.














Figure S1

A**B****C****D****E****F****Figure S2**

A**B****C****Figure S3**

TCGA data set (LGG/GBM)






Figure S4

A**B**